stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) EPS (diluted)
Ligand Pharmaceuticals Incorporated's EPS (diluted) for fiscal 2025 was $6.13, compared with −$0.22 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.24. Over the past ten years it has ranged from −$1.98 (fiscal 2022) to $31.85 (fiscal 2019); the current reading is higher than 82% of that period. Ligand Pharmaceuticals Incorporated ranks 27th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.13 | — |
| FY2024 | −$0.22 | — |
| FY2023 | $2.94 | — |
| FY2022 | −$1.98 | — |
| FY2021 | $3.34 | — |
| FY2020 | −$0.18 | — |
| FY2019 | $31.85 | 434.40% |
| FY2018 | $5.96 | 1,024.53% |
| FY2017 | $0.53 | — |
| FY2016 | −$0.08 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.43 | — |
| Jun 2026 | $2.22 | — |
| Mar 2026 | −$0.67 | — |
| Dec 2025 | $2.12 | (62.68%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $2.24 |
| PTCT PTC Therapeutics, Inc. compare | −$1.40 |
| ORKA Oruka Therapeutics, Inc. compare | −$2.12 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| IMVT Immunovant, Inc. compare | −$2.82 |
| IONS Ionis Pharmaceuticals, Inc. compare | −$3.46 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on LGND
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement